Novo Nordisk cancels further development of vatreptacog alfa as a treatment for Diabetes - 30-Sep-2012
Novo Nordisk has announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase IIIa trial adeptTM 2. A few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect.
Related News
Phase III trial for N9-GP(Novo Nordisk) treatment for Haemophilia B
FDA accepts BLA from Biogen for Eloctate for treatment of Haemophilia A
Biogen IDEC files rFVIII Fc at FDA for treatment of Haemophilia A
FDA expands approval of Corifact (CSL Behring) to manage surgical bleeding in adult and pediatric patients with Factor XIII Deficiency
Successful studies for rFVIIIFc and rFIXFc (Biogen/Swedish Orphan) for Haemopilia
BAX 855 enters Phase II/III study for Haemophilia
Biogen Idec files rFIXFc at FDA for treatment of Haemophilia B
Phase III results for BAX 326 (Baxter) for Haemophilia B
Related Haematology Information
Haematology Clinical Guidelines
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
AidsinfoBritish HIV Association guidelines for the treatment of TB/HIV coinfection 2011
British HIV AssociationHaematology Clinical Trials
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (DASAPOST)
Clinicaltrials.gov 27 February 2013A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Clinical Trials Register.eu 05 February 2013Haematology Medical Journal Abstracts
PedsQL™ Sickle Cell Disease Module: Feasibility, Reliability, and Validity
Pediatric Blood & Cancer 25 February 2013Validation of Variants in SLC28A3 and UGT1A6 as Genetic Markers Predictive of Anthracycline-Induced Cardiotoxicity in Children
Pediatric Blood & Cancer 25 February 2013Haematology Medical Apps
The Oncologist
Free
ACP PIER Database - Hematology
£37.29
Related Haematology Drugs
- EPREX 2000, 4000 AND 10000 IU/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
- FERRIPROX 100 MG/ML ORAL SOLUTION
- HAEMOCTIN 250 / HAEMOCTIN 500
- HUMAN ALBUMIN BIOTEST 20%
- ALPHANINE
- FLUVASTATIN 20MG CAPSULES
- TREDAPTIVE 1000 MG/20 MG MODIFIED RELEASE TABLETS
- FENOFIBRATE 267MG CAPSULES
- FERSADAY 100MG TABLETS
- MENADIOL DIPHOSPHATE TABLETS 10MG
- GALFER CAPSULES
- OCTANATE 50IU/ML
- FERRIPROX 500 MG FILM-COATED TABLETS
- HAEMOCTIN 250 / HAEMOCTIN 500
- ARANESP SURECLICK
- HAEMONINE 500 / HAEMONINE 1000
- FOLIC ACID 2.5MG/5ML ORAL SOLUTION
- FLUVASTATIN 40MG CAPSULES
- FEOSPAN SPANSULE CAPSULES
- RIENSO 30 MG/ML SOLUTION FOR INJECTION
- FANHDI 25 I.U./ML, 50 I.U./ML AND 100 I.U./ML
Advert for Healthcare Professionals only